In the last trading session, 2.36 million Altimmune Inc (NASDAQ:ALT) shares changed hands as the company’s beta touched 0.87. With the company’s per share price at $5.91 changed hands at -$0.2 or -3.27% during last session, the market valuation stood at $420.35M. ALT’s last price was a discount, traded about -151.1% off its 52-week high of $14.84. The share price had its 52-week low at $5.28, which suggests the last value was 10.66% up since then.
Analysts gave the Altimmune Inc (ALT) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.25. If we narrow down to specifics, the data shows that 0 out of 6 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended ALT as a Hold, 6 felt it is a Buy and 0 rated the stock as Underweight. Altimmune Inc’s EPS for the current quarter is expected to be -0.34.
Altimmune Inc (NASDAQ:ALT) trade information
Instantly ALT was in red as seen at the end of in last trading. With action -8.80%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -18.03%, with the 5-day performance at -8.80% in the red. However, in the 30-day time frame, Altimmune Inc (NASDAQ:ALT) is -15.33% down.
The consensus price target for the stock as assigned by Wall Street analysts is 25, meaning bulls need an upside of 76.36% from its current market value. According to analyst projections, ALT’s forecast low is 12 with 35 as the target high. To hit the forecast high, the stock’s price needs a -492.22% plunge from its current level, while the stock would need to soar -103.05% for it to hit the projected low.
Altimmune Inc (ALT) estimates and forecasts
Year-over-year growth is forecast to reach -99.27% down from the last financial year.
5 analysts are of the opinion that Altimmune Inc’s revenue for the current quarter will be 1k. The company’s revenue for the corresponding quarters a year ago was 37k and 5k respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -100.00%. The estimates for the next quarter sales put growth at -80.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 35.74%. The 2025 estimates are for Altimmune Inc earnings to increase by 18.75%, but the outlook for the next 5-year period is at -0.36% per year.
ALT Dividends
Altimmune Inc is expected to release its next quarterly earnings report in March.
VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 6.9301% or 4.91 million shares worth $32.63 million as of 2024-06-30.
Among Mutual Funds, the top two as of Sep 30, 2024 were Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF . With 2.58 shares estimated at $15.27 million under it, the former controlled 3.63% of total outstanding shares. On the other hand, iShares Russell 2000 ETF held about 2.79% of the shares, roughly 1.99 shares worth around $11.74 million.
